Paralympic Basketball: a new season begins for Volpi Rosse Menarini
FLORENCE, Italy, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Heart, passion, and the determination to overcome challenges. The Volpi Rosse Menarini are once again setting their sights on the hoop as they make their grand entrance at the prestigious Palazzo Vecchio. The wheelchair basketball team from the Tuscan capital is ready to start the National Serie A FIPIC (Italian Wheelchair Basketball Federation) Championship with renewed ambition. Founded in 2005 as the first wheelchair basketball team in Tuscany, Wheelchair Sport Florence is the kind of organisation where the integration of people with disabilities revolves around doing things together and setting an example with the passion, talent, and determination that its athletes exhibit in every game they play. Menarini, as the title sponsor, has been alongside this association since 2011. “These athletes making it to Serie A represent what it means to exceed one’s perceived limits,” stated Valeria Speroni Cardi, Menarini's Communications Director. The pharmaceutical multinational has always been closely connected to the world of sports, as confirmed by its support for another wheelchair basketball team, Club Joventut Badalona, competing in the Spanish Serie A.
“Today, we are sending the message that nothing is impossible. In cases like these, sport is one of the best examples of how, with courage and persistence, determination and conviction, many obstacles can be overcome,” said Cosimo Guccione, the Councillor for Sport of the Municipality of Florence, representing the authorities. He then added: “I would like to thank Menarini, which has embraced this project for years and supports this reality. To the team, the staff, and everyone who collaborates and supports this: you are the pride of Florence.”
“We wanted to create a very young base of athletes who have yet to ‘blossom’ into top players, but have enormous potential,” explained Ivano Nuti, President of the Volpi Rosse Menarini. “The players we have this year were the strongest in the entire national youth pathway,” he added. The new coach, Fabio Castellucci, who previously served as the head coach for the Under-22 National Team, “will be an added value for the team, as nearly all of them have already worked with him while wearing the blue jersey.”
The Florentine team is the youngest in the championship, as confirmed by the age of most of the players who will be guided by coach Castellucci. “I am excited about this new experience. I am familiar with the team’s journey over these years, thanks to Menarini's support because without them, none of this would be possible,” he said. Captain Samuele Cini, a player and a soon-to-be graduate student, said: “We are all-around athletes, and our main goal is to win. Clearly, this cannot be achieved without fun. We are a team of young men all of the same age. As captain, I often try to mediate, and in difficult moments, we help each other out."
One of the new arrivals, Salim Chakir, finally conveyed a message to the many young people facing similar circumstances. “Believing in your own abilities and giving 100% will always lead you to achieve all your goals. This is the message we want to convey, a broader message that can apply to individuals facing challenges like us as well as non-disabled individuals,” concluded the young Florentine basketball player.
For more information:
Press Office LaPresse - email@example.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/71449d92-bf5f-493e-be1c-f7070a83e2e6To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Managers’ transactions9.12.2023 18:12:40 CET | Press release
December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has received notice pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transaction related to shares in BioPorto made by persons discharging managerial responsibilities in BioPorto and/or persons closely related with them. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Singer Asefzadeh Family Holding Trust 2. Reason for the notification a) Position/status Closely associated person to Michael S. Singer, member of the Board of Directors of BioPorto A/S b) Initial notification/amendment Initial notification 3. Details of the issuer a) Name BioPorto A/S b) LEI 5299004SWFL5JAN4W830 4. Details of the transaction(s) a) Description of the financial instrument type of instrument and Identification code Shares, ISIN code DK0011048619 b) Nature o
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)9.12.2023 18:00:00 CET | Press release
Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcoritamab Results presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition include data from an optimized step-up dosing schedule for FL patients showing meaningful reduction in risk and severity of cytokine release syndrome (CRS) Follicular lymphoma is the second most common form of non-Hodgkin’s lymphoma, is considered incurable and can be difficult to treat in the R/R setting Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) todayannounced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demo
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG51019.12.2023 18:00:00 CET | Press release
Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancersTwo poster presentations include recent data updates and additional data not included in the ASH abstracts Galapagos to host a Key Opinion Leader (KOL) event with live webcast on Sunday, 10 December 2023 at 11:00 am PT/20:00 CET Mechelen, Belgium; 9 December 2023, 18:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) topresent additional encouraging clinical data from the ongoing Phase 1/2 CD19 CAR-T studies, EUPLAGIA-1 with GLPG5201 and ATALANTA-1 with GLPG5101, in patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter transformation, and non-Hodgkin lymphoma (rrNHL), during two poster sessions at the 65th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, from 9-12 December. “We are very pleased to share promising new data from o
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A9.12.2023 17:30:00 CET | Press release
Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of trauma 1Safety results were consistent with previous studies of Hemlibra, with no new safety signals observed 1The HAVEN 7 study was developed in collaboration with the haemophilia A community, to generate additional evidence for the prophylactic treatment of infants with haemophilia A Basel, 09 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab) in previously untreated or minimally treated infants with severe haemophilia A without factor VIII inhibitors. Results showed that Hemlibra achieved meaningful
Bulletin from Annual General Meeting in SkiStar AB9.12.2023 16:00:00 CET | Press release
At SkiStar AB (publ)’s annual general meeting, held in Sälen on 9 December 2023, the following decisions were made. A dividend of SEK 2.60 per share was adopted. Record day 12 December 2023.Lena Apler, Fredrik Paulsson, Gunilla Rudebjer, Anders Sundström, Anders Svensson and Vegard Søraunet were re-elected to the board and Carina Åkerström was elected as new board member.Anders Sundström was re-elected chairman of the board.Board fees, including committee fees, were raised to a total of SEK 2,890,000 (2022: SEK 2,810,000). The fees shall be distributed as follows: SEK 670,000 (650,000) to the chairman of the board and SEK 310,000 (300,000) each to the other non-executive directors. Audit committee members will receive total fees of SEK 240,000 (unchanged), distributed as follows: SEK 120,000 to the committee chairman and SEK 60,000 to each of the other two members. Remuneration committee members will receive total fees of SEK 120,000 (unchanged), distributed as follows: SEK 60,000 to t